Correlation Between InMode and Crispr Therapeutics

Can any of the company-specific risk be diversified away by investing in both InMode and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining InMode and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between InMode and Crispr Therapeutics AG, you can compare the effects of market volatilities on InMode and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in InMode with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of InMode and Crispr Therapeutics.

Diversification Opportunities for InMode and Crispr Therapeutics

0.04

Correlation Coefficient

InMode  Crispr Therapeutics

Significant diversification

The 3 months correlation between InMode and Crispr is 0.04. Overlapping area represents the amount of risk that can be diversified away by holding InMode and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and InMode is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on InMode are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of InMode i.e., InMode and Crispr Therapeutics go up and down completely randomly.

Pair Corralation between InMode and Crispr Therapeutics

Given the investment horizon of 90 days InMode is expected to generate 6.67 times less return on investment than Crispr Therapeutics. But when comparing it to its historical volatility, InMode is 2.11 times less risky than Crispr Therapeutics. It trades about 0.03 of its potential returns per unit of risk. Crispr Therapeutics AG is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  4,864  in Crispr Therapeutics AG on June 30, 2025 and sell it today you would earn a total of  1,303  from holding Crispr Therapeutics AG or generate 26.79% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

InMode  vs.  Crispr Therapeutics AG

InMode

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in InMode are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound primary indicators, InMode is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders.

Crispr Therapeutics

Risk-Adjusted Performance

Fair

Compared to the overall equity markets, risk-adjusted returns on investments in Crispr Therapeutics AG are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Crispr Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with InMode and Crispr Therapeutics

The main advantage of trading using opposite InMode and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if InMode position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.

The idea behind InMode and Crispr Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.